Spectrum Pharmaceuticals Aktie [WKN: 164623 / ISIN: US84763A1088]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Spectrum Pharmaceuticals IncShs

20.07.23		Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote "FOR” Proposed Transaction with Assertio Holdings, Inc. (Businesswire)
03.07.23		IMPORTANT ALERT: Halper Sadeh LLC Investigates FOCS, ASRT, MDWT, SPPI (PR Newswire)
17.05.23		Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (Businesswire)
09.05.23		Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update (Businesswire)
02.05.23		SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVT, NATI, SPPI (PR Newswire)
27.04.23		SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, SPPI, HOTH (PR Newswire)
25.04.23		Assertio Holdings To Acquire Spectrum Pharmaceuticals; ASRT Stock Tumble In Pre-market (RTTNews)
22.03.23		Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update (Businesswire)
17.03.23		Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update (Businesswire)
08.02.23		Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services (Businesswire)
02.02.23		SPPI FINAL DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - SPPI (PR Newswire)
31.01.23		Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results (Businesswire)
26.01.23		ROSEN, NATIONAL TRIAL LAWYERS, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SPPI (PR Newswire)
26.01.23		Spectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff (Businesswire)
18.01.23		ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action- SPPI (PR Newswire)
11.01.23		ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action- SPPI (PR Newswire)
04.01.23		Spectrum Pharmaceuticals Announces Management Changes (Businesswire)
04.01.23		ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action- SPPI (PR Newswire)
27.12.22		ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - SPPI (PR Newswire)
27.12.22		Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff (Businesswire)
21.12.22		ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - SPPI (PR Newswire)
14.12.22		SPPI INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPI (PR Newswire)
06.12.22		Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors (Businesswire)
05.12.22		Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff (Businesswire)
25.11.22		FDA Rejects Spectrum's Poziotinib, As Expected, Company To Cut R&D Workforce By 75% (RTTNews)
25.11.22		Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection (Businesswire)
10.11.22		Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (Businesswire)
03.11.22		Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update (Businesswire)
01.11.22		ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - SPPI (PR Newswire)
26.10.22		Biotech Stocks Facing FDA Decision In November 2022 (RTTNews)
21.10.22		Spectrum's Rolvedon Injection Ready To Sell Into Estimated $2 Bln Market (RTTNews)
21.10.22		Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection (Businesswire)
23.09.22		Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing (Businesswire)
22.09.22		Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting (Businesswire)
10.09.22		Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022 (Businesswire)
09.09.22		Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection (Businesswire)
05.09.22		Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022 (Businesswire)
27.08.22		Biotech Stocks Facing FDA Decision In September (RTTNews)
11.08.22		Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (Businesswire)
29.07.22		Spectrum Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update (Businesswire)
02.06.22		Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences (Businesswire)
26.05.22		Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response (Businesswire)
17.05.22		Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference (Businesswire)
12.05.22		Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (Businesswire)
11.05.22		Spectrum Pharma Names Nora Brennan CFO - Quick Facts (RTTNews)
11.05.22		Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer (Businesswire)
06.05.22		Spectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate Update (Businesswire)
05.05.22		Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors (Businesswire)
11.04.22		Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim (Businesswire)
04.04.22		Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Solana noch in diesem Jahr bei 300 US-Dollar?

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

BlackRocks Bitcoin-ETF überholt Gold-ETF

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.11.2024 10:54
Kaufwert:	EUR
	Hinzufügen Speichern